Poor
Mostly Aligned
Patient Risk:
Low
Summary
Some statements are supported by the provided label excerpts (plaque psoriasis indication, topical once-daily use concept, no contraindications, AhR mechanism as agonist, and external use), but several efficacy/biology explanations and side-effect characterizations are not directly supported as written. The response also omits key label-required usage details (e.g., thin layer, wash hands guidance, affected lesions only/avoid unaffected areas) and includes at least one claim that cannot be verified from the provided excerpts (brand name mapping and availability phrasing).
Category Scores
Accurate Statements
Tapinarof is a prescription medicine.
Not explicitly stated in provided excerpts.
Tapinarof is used to treat plaque psoriasis.
1.1 Plaque Psoriasis: “VTAMA cream is indicated for the topical treatment of plaque psoriasis in adults.”
Tapinarof is used as a topical cream.
2 Dosage and Administration / 1.1- topical treatment language; also 16 How supplied describes cream for topical use.
Tapinarof works by modulating inflammation in skin cells.
Not directly stated in provided excerpts; label states AhR agonist and “specific mechanisms … unknown.”
Tapinarof targets the aryl hydrocarbon receptor (AhR) pathway.
11 Description: “Tapinarof is an aryl hydrocarbon receptor agonist.”; 12.1: “Tapinarof is an aryl hydrocarbon receptor (AhR) agonist.”
The aryl hydrocarbon receptor (AhR) pathway affects immune signaling and inflammation in the skin.
Not stated in provided excerpts.
By targeting the aryl hydrocarbon receptor (AhR) pathway, tapinarof helps reduce psoriasis-related inflammation and symptoms.
Not directly stated; provided excerpts do not explicitly link to “reduce inflammation and symptoms.”
Tapinarof is applied to affected areas of the skin.
2 Dosage and Administration: “Apply a thin layer of VTAMA cream to affected areas once daily.”
Tapinarof is applied as directed by a clinician.
General compliance guidance not directly stated in provided excerpts.
Common side effects reported with topical tapinarof include application-site reactions such as redness.
Provided excerpts mention “application site reactions” in atopic dermatitis trials, but do not specify “redness.”
Common side effects reported with topical tapinarof include application-site reactions such as irritation.
Provided excerpts include “application site reactions” in AD trials, but do not specify “irritation.”
Tapinarof is marketed under the brand name Vtama for plaque psoriasis.
Provided label excerpt uses “VTAMA cream” for plaque psoriasis indication.
Availability of tapinarof depends on local prescribing rules and pharmacy supply.
Not addressed in provided excerpts.
Tapinarof is applied to affected areas of the skin.
2 Dosage and Administration: “Apply a thin layer of VTAMA cream to affected areas once daily.”
The aryl hydrocarbon receptor (AhR) pathway affects immune signaling and inflammation in the skin.
Not stated in provided excerpts.
Unsupported Statements
Tapinarof works by modulating inflammation in skin cells.
The label excerpt states tapinarof is an AhR agonist and that “specific mechanisms … are unknown.” It does not explicitly state “modulating inflammation in skin cells.”
Tapinarof helps reduce psoriasis-related inflammation and symptoms.
Provided excerpts do not explicitly claim that tapinarof reduces psoriasis-related inflammation and symptoms; efficacy endpoints are described without this specific causal phrasing.
The aryl hydrocarbon receptor (AhR) pathway affects immune signaling and inflammation in the skin.
Not stated in provided excerpts.
Tapinarof is applied as directed by a clinician.
While dosing instructions exist, the phrase “as directed by a clinician” is not present in provided excerpts.
Common side effects reported with topical tapinarof include application-site reactions such as redness.
Label excerpts mention application site reactions but do not specify redness.
Common side effects reported with topical tapinarof include application-site reactions such as irritation.
Label excerpts mention application site reactions but do not specify irritation.
Availability of tapinarof depends on local prescribing rules and pharmacy supply.
Not addressed in provided excerpts.
Contradictions
Important Omissions
Dosage specifics: “Apply a thin layer … once daily.”
Importance:
Moderate
Handwashing instruction: “Wash hands after application, unless … hands.”
Importance:
Moderate
Use restrictions: “not for oral, ophthalmic, or intravaginal use” and “for external use only.”
Importance:
Moderate
Affected-lesion-only instruction: “apply … to affected skin lesions only and avoid unaffected areas of skin.”
Importance:
Moderate
Pediatric/indication age limitation (plaque psoriasis not established in pediatric patients).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No direct contraindication conflicts or explicit unsafe route-of-use claims were made. However, multiple mechanistic explanations and side-effect specifics were not supported by the provided excerpts, and omission of key application instructions could affect correct use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements (especially mechanism/inflammation claims and specific side-effect descriptions like redness/irritation) are not supported verbatim by the provided label excerpts, and important dosing/administration instructions are omitted.
Suggested Improvement
Restrict mechanistic and symptom-reduction claims to what the label states (AhR agonist; specific mechanisms unknown) and replace side-effect examples with those listed in the label excerpts (e.g., application site reactions as a category without specifying redness/irritation). Include label dosing/administration details: thin layer once daily, affected lesions only/avoid unaffected skin, wash hands guidance, and external-use/route restrictions.